Cancer drug duo trial halted after enrolling just one patient
NCT ID NCT06006923
Summary
This study aimed to see if adding the drug regorafenib to the approved immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced colorectal cancer that has a specific genetic marker (MSI-H). The trial was designed in two parts: first testing safety and early signs of effectiveness in a small group, then randomly assigning more patients to compare the two treatment approaches. The study was terminated early, having enrolled only one participant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI-H COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.